
  
    
      
        Full_NNP text_NN
        The_DT disappointingly_RB slow_JJ progress_NN in_IN developing_VBG
        effective_JJ therapies_NNS for_IN ischemic_JJ stroke_NN has_VBZ led_VBN to_TO a_DT
        re-evaluation_JJ of_IN the_DT strategies_NNS for_IN stroke_NN drug_NN development_NN
        and_CC the_DT methods_NNS used_VBN in_IN clinical_JJ trials_NNS ._. Magnetic_JJ resonance_NN
        imaging_NN (_( MRI_NNP )_) techniques_NNS have_VBP been_VBN proposed_VBN and_CC have_VBP begun_VBN
        to_TO be_VB used_VBN in_IN stroke_NN trials_NNS as_IN a_DT means_NN of_IN optimizing_VBG
        patient_NN selection_NN and_CC as_IN a_DT direct_JJ measure_NN of_IN the_DT effect_NN of_IN
        treatments_NNS on_IN the_DT brain_NN ._.
        One_CD objective_NN in_IN all_DT clinical_JJ trials_NNS is_VBZ the_DT selection_NN of_IN
        a_DT sample_NN that_WDT is_VBZ sufficiently_RB homogeneous_JJ to_TO reduce_VB the_DT
        statistical_JJ variance_NN of_IN the_DT data_NNS and_CC thereby_RB optimize_NN the_DT
        sensitivity_NN of_IN the_DT design_NN to_TO detecting_VBG a_DT therapeutic_JJ
        response_NN ,_, while_IN remaining_VBG representative_NN of_IN the_DT population_NN
        of_IN interest_NN ._. Ischemic_NNP stroke_NN trials_NNS have_VBP traditionally_RB
        sought_VBN to_TO limit_VB the_DT range_NN of_IN disease_NN studied_VBD according_VBG to_TO
        one_CD or_CC more_JJR of_IN several_JJ dimensions_NNS ,_, such_JJ as_IN clinical_JJ
        severity_NN at_IN the_DT time_NN of_IN enrollment_NN ,_, exclusion_NN of_IN
        non-ischemic_JJ causes_NNS for_IN the_DT clinical_JJ syndrome_NN ,_, lesion_NN
        location_NN and_CC vascular_NN territory_NN ,_, stroke_NN mechanism_NN ,_, and_CC
        co-morbidities_JJ ._. These_DT dimensions_NNS have_VBP been_VBN assessed_VBN in_IN the_DT
        modern_JJ era_NN of_IN stroke_NN clinical_JJ trials_NNS by_IN clinical_JJ criteria_NNS
        at_IN the_DT bedside_NN ,_, usually_RB aided_VBN by_IN the_DT exclusion_NN of_IN cerebral_JJ
        hemorrhage_NN or_CC other_JJ non-ischemic_JJ pathology_NN by_IN non-contrast_JJ
        computed_JJ tomography_NN (_( CT_NNP )_) scan_VB as_IN the_DT only_JJ imaging_NN tool_NN
        required_VBN ._. Except_IN for_IN the_DT trials_NNS of_IN intravenous_JJ recombinant_JJ
        tissue-plasminogen_JJ activator_NN (_( rt-_NN PA_NNP )_) in_IN the_DT treatment_NN of_IN
        ischemic_JJ stroke_NN within_IN the_DT first_JJ 3_CD h_NN [_NN 1_CD ]_NN ,_, this_DT traditional_JJ
        approach_NN has_VBZ lead_VBN to_TO no_DT approved_VBD therapies_NNS for_IN stroke_NN ,_, and_CC
        has_VBZ lead_VBN to_TO a_DT great_JJ degree_NN of_IN pessimism_NN with_IN regard_NN to_TO
        thrombolysis_NNS beyond_IN 3_CD h_NN and_CC with_IN regard_NN to_TO the_DT concept_NN of_IN
        neuroprotection_NN in_IN stroke_NN ._.
        Because_IN several_JJ imaging_NN modalities_NNS may_MD provide_VB more_RBR
        accurate_JJ and_CC specific_JJ information_NN than_IN a_DT clinical_JJ
        assessment_NN and_CC a_DT normal_JJ CT_NNP scan_VB ,_, it_PRP has_VBZ been_VBN proposed_VBN that_IN
        positive_JJ imaging_NN diagnoses_NNS would_MD improve_VB patient_NN selection_NN
        toward_IN the_DT goal_NN of_IN a_DT more_JJR optimal_NN target_NN sample_NN for_IN stroke_NN
        clinical_JJ trials_NNS ,_, a_DT sample_NN selected_VBN based_VBN on_IN an_DT imaging_NN
        diagnosis_NN of_IN a_DT pathology_NN that_IN the_DT drug_NN is_VBZ hypothesized_VBN to_TO
        treat_VB ;_: for_IN example_NN ,_, an_DT arterial_NN occlusion_NN or_CC perfusion_NN
        defect_NN for_IN thrombolytic_JJ drugs_NNS ._. This_DT principle_NN has_VBZ been_VBN
        supported_VBN by_IN the_DT results_NNS of_IN the_DT intra-arterial_JJ
        pro-urokinase_JJ stroke_NN study_NN ,_, PROACT_NNP II_NNP [_NN 2_CD ]_NN ._. Prior_RB attempts_VBZ
        to_TO prove_VB the_DT efficacy_NN of_IN thrombolysis_NNS initiated_VBN between_IN 3_CD
        and_CC 6_CD h_NN from_IN onset_NN without_IN a_DT positive_JJ diagnosis_NN of_IN arterial_NN
        occlusion_NN or_CC perfusion_NN defect_NN have_VBP not_RB been_VBN successful_JJ [_NN 3_CD ,_,
        4_CD ,_, 5_CD ]_NN ._. Patients_NNS in_IN PROACT_NNP II_NNP [_NN 2_CD ]_NN ,_, however_RB ,_, were_VBD selected_VBN
        based_VBN on_IN evidence_NN of_IN arterial_NN occlusions_NNS at_IN the_DT M_NNP 1_CD or_CC M_NNP 2_CD
        levels_NNS of_IN the_DT middle_JJ cerebral_JJ artery_NN by_IN conventional_JJ
        arteriography_NN ,_, and_CC a_DT significant_JJ clinical_JJ benefit_NN was_VBD
        observed_VBN when_WRB thromboly-sis_JJ was_VBD initiated_VBN up_IN to_TO 6_CD h_NN from_IN
        symptom_NN onset_NN (_( median_JJ time_NN to_TO treat_VB ,_, 5_CD ._. 3_CD h_NN )_) ._. Whereas_IN trials_NNS
        of_IN intravenous_JJ (_( IV_NNP )_) thrombolysis_NNS between_IN 3_CD and_CC 6_CD h_NN in_IN a_DT
        general_JJ sample_NN of_IN ischemic_JJ stroke_NN patients_NNS were_VBD not_RB
        positive_JJ ,_, selection_NN of_IN the_DT optimal_NN subgroup_NN by_IN imaging_NN
        diagnosis_NN of_IN the_DT appropriate_JJ arterial_NN lesion_NN was_VBD an_DT
        effective_JJ strategy_NN in_IN this_DT time_NN period_NN for_IN PROACT_NNP II_NNP ._. This_DT
        study_NN contradicted_JJ the_DT increasingly_RB promoted_VBN hypothesis_NNS
        that_WDT treatment_NN of_IN stroke_NN by_IN thrombol-ysis_JJ (_( or_CC any_DT therapy_NN )_)
        beyond_IN 3_CD h_NN would_MD not_RB be_VB successful_JJ ._. Selection_NN of_IN the_DT
        optimal_NN target_NN population_NN by_IN angiography_NN led_VBN to_TO slower_JJR
        recruitment_NN and_CC a_DT more_RBR expensive_JJ trial_NN ,_, but_CC to_TO a_DT successful_JJ
        result_NN ._. The_DT results_NNS of_IN that_DT trial_NN suggested_VBD that_IN a_DT more_RBR
        prolonged_JJ study_NN duration_NN ,_, increased_VBN expense_NN and_CC potential_JJ
        delay_NN in_IN treatment_NN to_TO complete_VB a_DT screening_NN test_NN may_MD be_VB
        justified_JJ by_IN the_DT greater_JJR chance_NN of_IN demonstrating_VBG
        therapeutic_JJ success_NN using_VBG a_DT more_RBR homogeneous_JJ and_CC rational_JJ
        selection_NN of_IN patients_NNS ._.
        The_DT appeal_NN of_IN MRI_NNP methods_NNS is_VBZ that_IN ,_, whereas_IN the_DT standard_JJ
        CT_NNP examination_NN of_IN acute_JJ ischemic_JJ stroke_NN will_MD typically_RB
        appear_VB normal_JJ in_IN the_DT first_JJ hours_NNS after_IN stroke_NN onset_NN ,_, the_DT
        methods_NNS of_IN magnetic_JJ resonance_NN angiography_NN ,_, perfusion_NN
        weighted_JJ imaging_NN (_( PWI_NNP )_) ,_, and_CC diffusion_NN weighted_JJ imaging_NN
        (_( DWI_NNP )_) provide_VB information_NN on_IN arterial_NN patency_NN ,_, tissue_NN blood_NN
        flow_NN ,_, and_CC parenchymal_NN injury_NN from_IN the_DT earliest_JJS times_NNS after_IN
        onset_NN of_IN ischemic_JJ symptoms_NNS in_IN a_DT brief_JJ ,_, non-invasive_JJ
        examination_NN ._. DWI_NNP (_( Fig_NNP ._. 1_LS )_) detects_NNS tissue_NN injury_NN within_IN
        minutes_NNS of_IN ischemia_NN ,_, has_VBZ high_JJ sensitivity_NN and_CC specificity_NN
        for_IN the_DT diagnosis_NN of_IN ischemic_JJ stroke_NN ,_, and_CC permits_VBZ
        measurement_NN of_IN lesion_NN volumes_NNS that_WDT correlate_VBP with_IN clinical_JJ
        severity_NN and_CC prognosis_NN [_NN 6_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ,_, 10_CD ,_, 11_CD ,_, 12_CD ]_NN ._. If_IN
        untreated_JJ ,_, the_DT lesion_NN seen_VBN with_IN DWI_NNP typically_RB enlarges_NNS over_IN
        hours_NNS to_TO days_NNS and_CC will_MD progress_VB to_TO infarction_NN ._. PWI_NNP depicts_VBZ
        focal_JJ cerebral_JJ ischemia_NN ._. The_DT volume_NN of_IN ischemic_JJ tissue_NN seen_VBN
        with_IN PWI_NNP ,_, in_IN the_DT majority_NN of_IN cases_NNS ,_, is_VBZ greater_JJR than_IN the_DT
        region_NN of_IN parenchymal_NN injury_NN evident_JJ on_IN DWI_NNP ,_, and_CC this_DT
        diffusion-perfusion_JJ mismatch_NN is_VBZ considered_VBN to_TO be_VB a_DT marker_NN
        of_IN the_DT ischemic_JJ penumbra_NN (_( Fig_NNP ._. 2_LS )_) ,_, the_DT tissue_NN at_IN greatest_JJS
        risk_NN for_IN infarct_NN progression_NN [_NN 13_CD ,_, 14_CD ,_, 15_CD ,_, 16_CD ,_, 17_CD ,_, 18_CD ,_, 19_CD ,_,
        20_CD ,_, 21_CD ]_NN ._. Furthermore_RB ,_, increasing_VBG theoretical_JJ ,_, experimental_JJ ,_,
        and_CC clinical_JJ evidence_NN suggests_VBZ that_IN MRI_NNP using_VBG magnetic_JJ
        susceptibility_NN weighted_JJ pulse_NN sequences_NNS may_MD be_VB sensitive_JJ to_TO
        the_DT early_JJ detection_NN of_IN hemorrhage_NN [_NN 22_CD ,_, 23_CD ,_, 24_CD ]_NN ._. Although_IN
        prospective_JJ comparisons_NNS of_IN MRI_NNP and_CC CT_NNP for_IN sensitivity_NN to_TO
        hemorrhage_NN detection_NN have_VBP yet_RB to_TO be_VB reported_VBN ,_, the_DT proper_JJ
        acquisition_NN and_CC interpretation_NN of_IN MRI_NNP can_MD eliminate_VB the_DT
        need_NN for_IN a_DT screening_NN CT_NNP scan_VB and_CC regain_VB some_DT of_IN the_DT time_NN
        spent_VBD on_IN adding_VBG a_DT MRI_NNP examination_NN to_TO a_DT screening_NN
        evaluation_NN ._. The_DT target_NN pathology_NN revealed_VBN by_IN MRI_NNP also_RB
        represents_VBZ the_DT biological_JJ marker_NN of_IN the_DT disease_NN that_WDT can_MD
        serve_VB as_IN a_DT surrogate_JJ measure_NN for_IN assessing_VBG the_DT effects_NNS of_IN a_DT
        therapy_NN ._.
        Three_CD potential_JJ uses_NNS of_IN MRI_NNP in_IN clinical_JJ trials_NNS have_VBP been_VBN
        proposed_VBN :_: patient_NN selection_NN ,_, proof_NN of_IN pharmacologic_JJ
        principle_NN ,_, and_CC as_IN an_DT outcome_NN measure_NN ._.
        In_IN using_VBG MRI_NNP as_IN a_DT selection_NN criterion_NN in_IN patient_NN
        selection_NN (_( Table_NNP 1_LS )_) ,_, the_DT goal_NN would_MD be_VB a_DT sample_NN based_VBN on_IN a_DT
        positive_JJ imaging_NN diagnosis_NN of_IN a_DT pathology_NN rationally_RB linked_VBD
        to_TO the_DT drug_NN 's_POS mechanisms_NNS of_IN action_NN ._. Requiring_NNP a_DT positive_JJ
        diagnosis_NN of_IN acute_JJ ischemic_JJ injury_NN by_IN DWI_NNP would_MD ideally_RB
        assure_VB that_IN no_DT patients_NNS with_IN diagnoses_NNS mimicking_VBG stroke_NN are_VBP
        included_VBN in_IN the_DT sample_NN ,_, a_DT desirable_JJ objective_NN unachievable_JJ
        in_IN trials_NNS using_VBG bedside_NN impression_NN and_CC normal_JJ CT_NNP as_IN the_DT
        basis_NN of_IN inclusion_NN ._. The_DT goal_NN of_IN image-based_JJ patient_NN
        selection_NN is_VBZ to_TO narrow_VB the_DT range_NN of_IN patient_NN
        characteristics_NNS ,_, leading_VBG to_TO a_DT more_RBR homogeneous_JJ sample_NN ,_,
        reducing_VBG within-group_JJ variance_NN ,_, and_CC increasing_VBG the_DT
        statistical_JJ power_NN of_IN the_DT experimental_JJ design_NN to_TO demonstrate_VB
        efficacy_NN ._. Optimal_NNP patient_NN selection_NN would_MD be_VB based_VBN on_IN
        positive_JJ imaging_NN evidence_NN of_IN the_DT ischemic_JJ pathology_NN that_IN
        the_DT therapy_NN has_VBZ been_VBN developed_VBN to_TO treat_VB ._. The_DT simplest_JJS use_NN
        as_IN an_DT inclusion_NN criterion_NN would_MD include_VB the_DT presence_NN of_IN a_DT
        lesion_NN on_IN DWI_NNP to_TO increase_VB the_DT diagnostic_JJ certainty_NN of_IN
        ischemic_JJ stroke_NN ._. The_DT optimal_NN target_NN of_IN therapy_NN for_IN
        reperfusion_NN therapies_NNS would_MD be_VB patients_NNS with_IN evidence_NN of_IN an_DT
        arterial_NN occlusion_NN or_CC hypoper-fusion_JJ (_( Fig_NNP ._. 3_LS )_) [_NN 17_CD ,_, 25_CD ]_NN ._.
        Optimal_NNP selection_NN of_IN patients_NNS for_IN neuroprotective_JJ drugs_NNS
        would_MD be_VB acute_JJ lesions_NNS involving_VBG the_DT cerebral_JJ cortex_NN and_CC
        with_IN a_DT larger_JJR region_NN of_IN hypoperfusion_NN -_: the_DT
        diffusion-perfusion_JJ mismatch_NN indicative_JJ of_IN tissue_NN at_IN risk_NN
        for_IN infarction_NN (_( Fig_NNP ._. 2_LS and_CC Table_NNP 2_LS )_) ._. Patients_NNS might_MD also_RB be_VB
        excluded_VBN from_IN the_DT trial_NN at_IN screening_NN if_IN subacute_NN or_CC chronic_JJ
        lesions_NNS are_VBP found_VBN that_WDT may_MD confound_NN measurements_NNS of_IN lesion_NN
        volumes_NNS or_CC clinical_JJ severity_NN as_IN outcome_NN variables_NNS ._. Because_IN
        of_IN a_DT relatively_RB large_JJ error_NN of_IN measurement_NN associated_VBN with_IN
        small_JJ lesions_NNS [_NN 26_CD ]_NN ,_, lesions_NNS larger_JJR than_IN a_DT minimum_JJ volume_NN
        (_( eg_NN 5_CD cm_NN 3_LS )_) may_MD be_VB desirable_JJ ._. Furthermore_RB ,_, an_DT upper_JJ limit_NN
        of_IN lesion_NN volume_NN at_IN enrollment_NN would_MD permit_VB an_DT opportunity_NN
        for_IN lesion_NN growth_NN and_CC may_MD better_JJR differentiate_VB the_DT effect_NN
        on_IN lesion_NN size_NN of_IN an_DT effective_JJ treatment_NN from_IN placebo_NN ._.
        Selection_NN of_IN patients_NNS by_IN DWI_NNP is_VBZ also_RB optimally_RB suited_VBN for_IN
        using_VBG the_DT lesion_NN volume_NN change_NN as_IN a_DT direct_JJ measure_NN of_IN the_DT
        neuroprotective_JJ effect_NN of_IN the_DT drug_NN ._.
        The_DT proof_NN of_IN pharmacological_JJ principle_NN uses_VBZ MRI_NNP as_IN a_DT
        marker_NN of_IN response_NN to_TO therapy_NN ,_, replicating_VBG the_DT preclinical_JJ
        experiment_NN in_IN patients_NNS ._. Before_IN an_DT experimental_JJ stroke_NN
        therapy_NN is_VBZ brought_VBN from_IN the_DT laboratory_NN to_TO clinical_JJ trial_NN ,_,
        it_PRP is_VBZ necessary_JJ to_TO demonstrate_VB that_IN the_DT treatment_NN causes_NNS
        reduction_NN in_IN lesion_NN volume_NN in_IN experimental_JJ models_NNS ._. The_DT
        fundamental_JJ premise_NN of_IN drug_NN discovery_NN and_CC development_NN in_IN
        acute_JJ stroke_NN is_VBZ that_IN treatments_NNS that_WDT reduce_VBP lesion_NN size_NN are_VBP
        those_DT most_RBS likely_JJ to_TO lead_VB to_TO clinical_JJ benefit_NN ._. In_IN clinical_JJ
        trial_NN programs_NNS that_WDT depend_VBP solely_RB on_IN clinical_JJ endpoints_NNS as_IN
        indices_NNS of_IN benefit_NN ,_, drugs_NNS may_MD be_VB brought_VBN to_TO phase_VB III_NNP
        testing_NN -_: costing_VBG several_JJ years_NNS and_CC tens_NNS of_IN millions_NNS of_IN
        dollars_NNS -_: without_IN the_DT slightest_JJS evidence_NN that_IN the_DT drug_NN will_MD
        have_VB the_DT therapeutic_JJ effect_NN observed_VBD in_IN the_DT experimental_JJ
        model_NN ._. Only_RB a_DT safe_JJ and_CC acceptable_JJ dose_NN must_MD be_VB demonstrated_VBN
        by_IN the_DT end_NN of_IN phase_NN II_NNP ._. The_DT question_NN of_IN whether_IN the_DT
        treatment_NN causes_NNS reduction_NN of_IN lesion_NN volume_NN ,_, however_RB ,_, may_MD
        be_VB answerable_JJ in_IN the_DT study_NN of_IN 100_CD -_: 200_CD patients_NNS in_IN phase_NN II_NNP ,_,
        whereas_IN 5_CD -_: 10_CD times_NNS as_IN many_JJ patients_NNS are_VBP typically_RB tested_VBN in_IN
        phase_NN III_NNP studies_NNS to_TO evaluate_VB the_DT treatment_NN with_IN clinical_JJ
        endpoints_NNS ._. A_DT phase_NN II_NNP MRI_NNP endpoint_NN trial_NN to_TO replicate_VB the_DT
        preclinical_JJ experiment_NN in_IN a_DT patient_NN population_NN may_MD thus_RB be_VB
        a_DT rational_JJ and_CC cost-effective_JJ basis_NN of_IN deciding_VBG whether_IN to_TO
        proceed_VB with_IN phase_NN III_NNP testing_NN ._. A_DT positive_JJ lesion_NN outcome_NN
        study_NN in_IN late_JJ phase_NN II_NNP would_MD be_VB supportive_JJ of_IN the_DT decision_NN
        to_TO proceed_VB with_IN phase_NN III_NNP trials_NNS ._.
        MRI_NNP measurements_NNS have_VBP proven_VBN to_TO be_VB a_DT marker_NN of_IN clinical_JJ
        severity_NN measured_VBN by_IN stroke_NN scales_NNS [_NN 11_CD ,_, 15_CD ,_, 27_CD ,_, 28_CD ]_NN ,_, and_CC
        changes_NNS in_IN lesion_NN volume_NN over_IN time_NN are_VBP associated_VBN with_IN
        change_NN in_IN clinical_JJ severity_NN (_( Table_NNP 3_LS )_) [_NN 29_CD ]_NN ._. The_DT exact_JJ
        sample_NN size_NN that_WDT is_VBZ required_VBN for_IN detecting_VBG the_DT effect_NN of_IN
        lesion_NN volume_NN change_NN with_IN MRI_NNP will_MD depend_VB on_IN many_JJ factors_NNS
        in_IN the_DT design_NN of_IN a_DT trial_NN ._. The_DT citicoline_NN MRI_NNP trial_NN [_NN 29_CD ]_NN ,_,
        with_IN approximately_RB 40_CD evaluable_JJ patients_NNS per_IN group_NN ,_,
        approached_VBN but_CC did_VBD not_RB reach_VB significance_NN ._. Estimates_NNS based_VBN
        on_IN that_DT study_NN indicate_VBP that_IN 58_CD patients_NNS per_IN treatment_NN arm_NN
        would_MD have_VB been_VBN sufficient_JJ to_TO demonstrate_VB a_DT neuroprotective_JJ
        effect_NN in_IN patients_NNS ,_, a_DT sample_NN size_NN compatible_JJ with_IN typical_JJ
        phase_NN II_NNP sample_NN sizes_NNS ._. That_DT study_NN and_CC natural_JJ history_NN
        samples_NNS suggest_VBP that_IN a_DT sample_NN size_NN of_IN 50_CD -_: 100_CD should_MD be_VB
        sufficient_JJ to_TO demonstrate_VB a_DT neuro-protective_JJ effect_NN on_IN
        lesion_NN volume_NN in_IN patients_NNS ._.
        It_PRP is_VBZ proposed_VBN that_IN a_DT treatment_NN emergent_NN advantage_NN on_IN a_DT
        measure_NN of_IN lesion_NN volume_NN is_VBZ a_DT surrogate_NN of_IN clinical_JJ benefit_NN
        for_IN stroke_NN trials_NNS (_( Table_NNP 4_LS )_) ._. The_DT rationale_NN for_IN the_DT use_NN of_IN
        lesion_NN volume_NN as_IN a_DT surrogate_JJ measure_NN in_IN stroke_NN trials_NNS may_MD
        be_VB summarized_VBD as_IN follows_VBZ ._. Lesion_NNP volume_NN reduction_NN in_IN animal_NN
        models_NNS is_VBZ both_DT necessary_JJ and_CC sufficient_JJ evidence_NN of_IN
        neuroprotection_NN ._. The_DT clinical_JJ benefit_NN for_IN neuroprotective_JJ
        drugs_NNS is_VBZ mediated_JJ through_IN a_DT reduction_NN in_IN cell_NN death_NN and_CC
        brain_NN tissue_NN loss_NN ._. Drugs_NNS that_WDT reduce_VBP infarct_NN volume_NN are_VBP
        those_DT most_RBS likely_JJ to_TO cause_VB clinical_JJ benefit_NN ._.
        The_DT factors_NNS required_VBN for_IN validation_NN of_IN MRI_NNP as_IN a_DT
        surrogate_JJ marker_NN are_VBP summarized_VBD in_IN Table_NNP 5_CD ._. The_DT first_JJ four_CD
        of_IN these_DT requirements_NNS have_VBP been_VBN met_VBN (_( see_VB earlier_JJR discussion_NN
        and_CC cited_VBD references_NNS )_) ._. Confirmation_NNP of_IN the_DT validity_NN of_IN many_JJ
        of_IN these_DT features_NNS of_IN DWI_NNP and_CC PWI_NNP in_IN acute_JJ stroke_NN has_VBZ
        recently_RB come_VBN from_IN the_DT first_JJ prospective_JJ multicenter_NN stroke_NN
        trial_NN using_VBG MRI_NNP as_IN an_DT inclusion_NN and_CC primary_JJ outcome_NN
        measure_NN ,_, the_DT citicoline_NN MRI_NNP stroke_NN trial_NN [_NN 29_CD ]_NN ._. In_IN that_DT
        study_NN ,_, identical_JJ MRI_NNP hardware_NN and_CC software_NN were_VBD used_VBN in_IN 17_CD
        centers_NNS across_IN the_DT United_NNP States_NNPS to_TO study_VB 100_CD patients_NNS with_IN
        ischemic_JJ stroke_NN within_IN 24_CD h_NN of_IN onset_NN ._. Patients_NNS were_VBD
        randomly_RB assigned_VBN to_TO 500_CD mg_NN /_NN day_NN citicoline_NN or_CC placebo_NN ._.
        Diffusion_NNP and_CC perfusion_NN MRI_NNP were_VBD obtained_VBN before_IN treatment_NN ,_,
        and_CC 1_CD and_CC 12_CD weeks_NNS after_IN treatment_NN ._. Image_NN data_NNS processing_NN
        and_CC volumetric_JJ analysis_NN were_VBD performed_VBN at_IN a_DT single_JJ central_JJ
        laboratory_NN using_VBG a_DT single_JJ expert_NN reader_NN blinded_JJ to_TO patient_NN
        clinical_JJ severity_NN and_CC treatment_NN assignment_NN ._. The_DT primary_JJ MRI_NNP
        inclusion_NN criterion_NN was_VBD a_DT lesion_NN of_IN volume_NN 1_CD -_: 120_CD cm_NN 3_CD in_IN
        middle_JJ cerebral_JJ artery_NN territory_NN gray_JJ matter_NN ._. The_DT primary_JJ
        efficacy_NN endpoint_NN was_VBD a_DT change_NN in_IN lesion_NN volume_NN from_IN
        pretreatment_NN to_TO week_NN 12_CD ._. Although_IN the_DT primary_JJ efficacy_NN
        endpoint_NN of_IN an_DT effect_NN of_IN citicoline_NN on_IN lesion_NN growth_NN was_VBD
        numerically_RB different_JJ (_( 181_CD %_NN increase_NN in_IN lesion_NN volume_NN in_IN
        placebo_NN patients_NNS versus_CC 34_CD %_NN increase_NN for_IN citicoline_NN treated_VBD
        patients_NNS )_) ,_, it_PRP was_VBD not_RB statistically_RB significant_JJ ._. However_RB ,_,
        the_DT study_NN replicated_VBN the_DT findings_NNS of_IN other_JJ investigations_NNS
        regarding_VBG the_DT relationship_NN of_IN MRI-derived_NNP lesion_NN volumes_NNS to_TO
        patients_NNS '_POS clinical_JJ status_NN ._. Acute_NNP lesion_NN volumes_NNS by_IN DWI_NNP in_IN
        100_CD patients_NNS correlated_JJ significantly_RB with_IN acute_JJ clinical_JJ
        severity_NN on_IN NIH_NNP stroke_NN scale_NN scores_NNS (_( 
        r_LS =_SYM 0_CD ._. 64_CD )_) and_CC with_IN chronic_JJ lesion_NN
        volume_NN (_( 
        r_LS =_SYM 0_CD ._. 79_CD )_) ;_: the_DT chronic_JJ lesion_NN volume_NN
        by_IN T_NN 2_CD -_: weighted_JJ MRI_NNP significantly_RB correlated_JJ with_IN chronic_JJ
        NIH_NNP stroke_NN scale_NN score_NN (_( 
        r_LS =_SYM 0_CD ._. 63_CD )_) ._. The_DT strongest_JJS predictor_NN of_IN
        change_NN in_IN lesion_NN size_NN from_IN baseline_NN in_IN the_DT 81_CD patients_NNS who_WP
        completed_VBD their_PRP$ week_NN 12_CD assessment_NN was_VBD the_DT size_NN of_IN the_DT
        perfusion_NN abnormality_NN (_( 
        P_NN <_NN 0_CD ._. 0001_CD by_IN co-variance_JJ
        analysis_NN )_) ._. The_DT volume_NN change_NN over_IN the_DT 12_CD weeks_NNS of_IN
        observation_NN was_VBD significantly_RB related_VBN to_TO the_DT patient_NN 's_POS
        clinical_JJ improvement_NN ._. Patients_NNS meeting_VBG the_DT protocol_NN
        specified_VBD criterion_NN of_IN clinical_JJ improvement_NN (_( improvement_NN on_IN
        the_DT NIH_NNP stroke_NN scale_NN of_IN seven_CD points_NNS or_CC more_JJR )_) had_VBD a_DT
        significantly_RB more_RBR favorable_JJ response_NN on_IN the_DT lesion_NN volume_NN
        change_NN outcome_NN variable_JJ than_IN those_DT who_WP did_VBD not_RB improve_VB ._. The_DT
        differentiation_NN of_IN improved_VBN from_IN not_RB improved_VBN was_VBD present_JJ
        whether_IN the_DT lesion_NN volume_NN change_NN was_VBD assessed_VBN as_IN an_DT
        absolute_JJ decrease_NN (_( 74_CD %_NN versus_CC 36_CD %_NN )_) ,_, median_JJ change_NN (_( -_: 2_CD ._. 8_CD cm_NN
        3_CD versus_CC 3_CD ._. 7_CD cm_NN 3_LS )_) ,_, or_CC mean_VB (_( SE_NNP )_) change_NN (_( 3_CD ._. 8_CD [_NN 3_CD ._. 8_CD ]_NN cm_NN
        3_CD versus_CC 25_CD ._. 5_LS [_NN 6_CD ._. 8_CD ]_NN cm_NN 3_LS )_) (_( Table_NNP 5_LS )_) ._. This_DT prospective_JJ
        multicenter_NN ,_, centrally_RB analyzed_VBD trial_NN confirmed_VBD the_DT value_NN
        of_IN MRI_NNP as_IN a_DT marker_NN of_IN disease_NN severity_NN and_CC progression_NN in_IN
        stroke_NN trials_NNS ,_, and_CC indicated_VBD that_IN the_DT change_NN in_IN MRI_NNP lesion_NN
        size_NN is_VBZ likely_JJ to_TO predict_VB clinical_JJ improvement_NN in_IN clinical_JJ
        trials_NNS ._.
        The_DT fifth_JJ criterion_NN of_IN validation_NN ,_, the_DT concordance_NN of_IN
        effects_NNS on_IN clinical_JJ outcomes_NNS and_CC surrogate_JJ outcomes_NNS ,_,
        remains_VBZ to_TO be_VB demonstrated_VBN ._. Effective_NNP drugs_NNS will_MD show_VB
        benefit_NN on_IN both_DT clinical_JJ and_CC imaging_NN outcome_NN measures_NNS ._. The_DT
        citicoline_NN trials_NNS provide_VBP support_NN for_IN this_DT ,_, wherein_WRB trends_NNS
        on_IN both_DT clinical_JJ and_CC imaging_NN outcomes_NNS measures_NNS have_VBP been_VBN
        observed_VBN [_NN 29_CD ,_, 30_CD ,_, 31_CD ,_, 32_CD ]_NN ._. Ineffective_NNP drugs_NNS will_MD show_VB
        benefit_NN on_IN neither_DT clinical_JJ nor_CC imaging_NN outcome_NN measures_NNS ._.
        The_DT latter_NN has_VBZ been_VBN found_VBN for_IN the_DT Glycine_NNP Antagonist_NNP in_IN
        Neuroprotection_NNP (_( GAIN_NNP )_) trials_NNS ,_, which_WDT showed_VBD no_DT effect_NN on_IN
        clinical_JJ or_CC MRI_NNP surrogate_JJ outcomes_NNS [_NN 33_CD ,_, 34_CD ]_NN ._. This_DT
        comparison_NN is_VBZ only_RB meaningful_JJ if_IN studies_NNS are_VBP optimally_RB
        designed_VBN and_CC equally_RB powered_VBN to_TO show_VB effect_NN on_IN their_PRP$
        respective_JJ outcome_NN measures_NNS ;_: that_DT is_VBZ ,_, the_DT optimal_NN sample_NN
        size_NN for_IN imaging_NN studies_NNS may_MD be_VB too_RB small_JJ to_TO show_VB clinical_JJ
        effects_NNS ._. Possible_JJ explanations_NNS for_IN discordant_JJ clinical_JJ
        versus_CC surrogate_JJ marker_NN results_NNS are_VBP presented_VBN in_IN Table_NNP
        6_CD ._.
        The_DT concept_NN that_DT improvement_NN as_IN a_DT measure_NN of_IN brain_NN
        lesion_NN volume_NN is_VBZ a_DT proper_JJ surrogate_JJ outcome_NN for_IN destructive_JJ
        central_JJ nervous_JJ system_NN diseases_NNS has_VBZ been_VBN already_RB accepted_VBN
        by_IN academic_JJ and_CC regulatory_JJ communities_NNS alike_RB ._. Approval_NNP of_IN
        beta-interferon_JJ for_IN the_DT treatment_NN of_IN multiple_JJ sclerosis_NN was_VBD
        based_VBN ,_, in_IN part_NN ,_, on_IN lesion_NN volume_NN as_IN a_DT surrogate_JJ marker_NN of_IN
        disease_NN activity_NN ,_, even_RB though_IN the_DT surrogate_NN was_VBD not_RB
        considered_VBN fully_RB validated_JJ ._. A_DT surrogate_JJ outcome_NN measure_NN in_IN
        clinical_JJ trials_NNS does_VBZ not_RB need_VB to_TO be_VB fully_RB validated_JJ as_IN a_DT
        condition_NN of_IN drug_NN approval_NN ._. Recent_JJ changes_NNS to_TO the_DT Federal_NNP
        Food_NNP Drug_NNP and_CC Cosmetic_NNP Act_NNP ,_, which_WDT regulates_VBZ the_DT Food_NNP and_CC
        Drug_NNP Administration_NNP approval_NN process_NN ,_, have_VBP specified_VBN a_DT
        fast-track_JJ drug_NN designation_NN to_TO expedite_VB review_NN for_IN drugs_NNS
        that_WDT have_VBP "_'' the_DT potential_NN to_TO address_VB unmet_JJ medical_JJ needs_NNS for_IN
        serious_JJ and_CC life-threatening_JJ conditions_NNS "_'' [_NN 35_CD ]_NN ._. Drugs_NNS for_IN
        treatment_NN of_IN stroke_NN have_VBP fallen_VBN under_IN this_DT designation_NN ._. A_DT
        drug_NN must_MD ordinarily_RB have_VB a_DT beneficial_JJ effect_NN on_IN a_DT clinical_JJ
        endpoint_NN or_CC on_IN a_DT validated_JJ surrogate_JJ endpoint_NN to_TO
        demonstrate_VB effectiveness_NN ._. The_DT new_JJ regulations_NNS state_VBP that_IN a_DT
        drug_NN "_'' may_MD be_VB approved_VBN if_IN it_PRP has_VBZ an_DT effect_NN on_IN a_DT surrogate_JJ
        endpoint_NN that_WDT is_VBZ 
        reasonably_RB likely_JJ to_TO predict_VB clinical_JJ
        benefit_NN ._. Such_JJ surrogate_JJ endpoints_NNS are_VBP considered_VBN 
        not_RB to_TO be_VB validated_JJ because_IN ,_, while_IN
        suggestive_JJ of_IN clinical_JJ benefit_NN ,_, their_PRP$ relationship_NN to_TO
        clinical_JJ outcomes_NNS ,_, such_JJ as_IN morbidity_NN and_CC mortality_NN ,_, is_VBZ not_RB
        proven_VBN "_'' [_NN 35_CD ]_NN (_( emphasis_NN added_VBD )_) ._. The_DT issue_NN with_IN regard_NN to_TO
        MRI_NNP as_IN a_DT surrogate_NN in_IN stroke_NN trials_NNS is_VBZ whether_IN it_PRP is_VBZ
        '_POS reasonably_RB likely_JJ to_TO predict_VB clinical_JJ benefit_NN '_'' ._. The_DT
        hypothesis_NNS that_WDT neuroprotection_NN ,_, the_DT restriction_NN of_IN infarct_NN
        volume_NN ,_, is_VBZ reasonably_RB likely_JJ to_TO be_VB clinically_RB beneficial_JJ to_TO
        patients_NNS is_VBZ the_DT premise_NN of_IN virtually_RB all_DT acute_JJ stroke_NN drugs_NNS
        being_VBG developed_VBN ._. The_DT clinical_JJ data_NN already_RB discussed_VBN
        supports_VBZ the_DT value_NN of_IN measuring_VBG infarct_NN value_NN as_IN a_DT
        surrogate_NN ._.
        Strict_JJ validation_NN must_MD eventually_RB be_VB proven_VBN but_CC ,_, as_IN we_PRP
        see_VBP from_IN Food_NNP and_CC Drug_NNP Administration_NNP regulations_NNS ,_, it_PRP is_VBZ no_RB
        longer_RB required_VBN to_TO use_VB lesion_NN volume_NN by_IN MRI_NNP as_IN a_DT surrogate_JJ
        outcome_NN in_IN stroke_NN trials_NNS ._. A_DT benefit_NN on_IN the_DT surrogate_NN may_MD be_VB
        acceptable_JJ as_IN an_DT independent_JJ source_NN of_IN confirmatory_NN data_NNS in_IN
        support_NN of_IN a_DT clinical_JJ benefit_NN seen_VBN in_IN a_DT single_JJ trial_NN ._. The_DT
        question_NN ,_, therefore_RB ,_, is_VBZ no_RB longer_RB whether_IN MRI_NNP surrogates_NNS
        should_MD be_VB used_VBN in_IN trials_NNS ,_, but_CC how_WRB they_PRP should_MD be_VB used_VBN ._.
        The_DT pharmaceutical_JJ industry_NN has_VBZ taken_VBN the_DT initiative_NN in_IN
        investigating_VBG this_DT final_JJ step_NN in_IN validation_NN ._. The_DT results_NNS of_IN
        several_JJ industry-sponsored_JJ drug_NN trials_NNS using_VBG MRI_NNP as_IN a_DT
        surrogate_NN will_MD be_VB known_VBN over_IN the_DT next_JJ several_JJ years_NNS ,_, and_CC
        those_DT studies_NNS should_MD provide_VB the_DT most_RBS decisive_JJ information_NN
        regarding_VBG the_DT utility_NN of_IN MRI_NNP as_IN a_DT surrogate_JJ outcome_NN measure_NN
        in_IN stroke_NN trials_NNS ._. Three_CD multicenter_NN randomized_JJ clinical_JJ
        trials_NNS using_VBG MRI_NNP as_IN a_DT key_JJ selection_NN and_CC outcome_NN variable_JJ
        have_VBP been_VBN completed_VBN and_CC reported_VBN ._. Several_JJ other_JJ trials_NNS are_VBP
        in_IN progress_NN or_CC being_VBG planned_VBN ._.
        In_IN conclusion_NN ,_, there_EX have_VBP been_VBN concerns_NNS raised_VBN in_IN the_DT
        past_NN that_IN the_DT use_NN of_IN MRI_NNP in_IN stroke_NN clinical_JJ trails_NNS is_VBZ
        impractical_JJ for_IN technical_JJ and_CC logistical_JJ reasons_NNS (_( eg_NN scan_VB
        duration_NN and_CC availability_NN )_) ._. The_DT practical_JJ limitations_NNS have_VBP
        disappeared_VBN with_IN the_DT widespread_JJ availability_NN of_IN ultrafast_NN
        echoplanar_NN imaging_NN with_IN diffusion_NN and_CC perfusion_NN capability_NN
        on_IN commercial_JJ MRI_NNP scanners_NNS ._. A_DT highly_RB motivated_VBN ,_,
        well-coordinated_JJ center_NN can_MD perform_VB emergency_NN diffusion_NN and_CC
        perfusion_NN MRI_NNP with_IN a_DT latency_NN to_TO scan_VB and_CC scanning_VBG session_NN
        duration_NN comparable_JJ with_IN that_DT of_IN emergency_NN head_NN CT_NNP ._. There_EX
        are_VBP now_RB over_IN 100_CD centers_NNS worldwide_NN capable_JJ of_IN and_CC
        experienced_VBN in_IN performing_VBG these_DT types_NNS of_IN acute_JJ MRI_NNP
        examinations_NNS ._. Key_JJ design_NN issues_NNS with_IN regard_NN to_TO the_DT use_NN of_IN
        diffusion_NN and_CC perfusion_NN MRI_NNP in_IN stroke_NN trials_NNS are_VBP proposed_VBN
        in_IN Table_NNP 7_CD ._. MRI-based_NNP recruitment_NN into_IN trials_NNS with_IN a_DT time_NN
        window_NN of_IN 6_CD h_NN has_VBZ proven_VBN feasible_JJ ,_, as_IN has_VBZ specific_JJ
        selection_NN based_VBN on_IN lesion_NN size_NN ,_, location_NN ,_, and_CC the_DT
        diffusion-perfusion_JJ mismatch_NN ._. As_IN the_DT field_NN of_IN stroke_NN
        clinical_JJ trials_NNS examines_VBZ opportunities_NNS for_IN improving_VBG trial_NN
        design_NN ,_, positive_JJ imaging_NN diagnoses_NNS in_IN patient_NN selection_NN and_CC
        use_NN of_IN imaging_NN as_IN treatment_NN assessments_NNS is_VBZ likely_JJ to_TO assume_VB
        an_DT increasingly_RB useful_JJ role_NN ._. Patient_NNP selection_NN and_CC outcomes_NNS
        based_VBN exclusively_RB on_IN clinical_JJ assessment_NN and_CC
        non-hemorrhagic_JJ CT_NNP scans_VBZ may_MD no_RB longer_RB be_VB appropriate_JJ for_IN
        all_DT trials_NNS ._.
      
    
  
